{"name":"Pascoe Pharmazeutische Praeparate GmbH","slug":"pascoe-pharmazeutische-praeparate-gmbh","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"HDC","genericName":"HDC","slug":"hdc","indication":"Detoxification support (homeopathic indication)","status":"phase_3"},{"name":"Pascoflair","genericName":"Pascoflair","slug":"pascoflair","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"HDC","genericName":"HDC","slug":"hdc","phase":"phase_3","mechanism":"HDC is a homeopathic combination remedy designed to support detoxification and drainage of metabolic waste products.","indications":["Detoxification support (homeopathic indication)"],"catalyst":""},{"name":"Pascoflair","genericName":"Pascoflair","slug":"pascoflair","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxQcWJPM1VBVUtZMklibGJ0UXMxZmJUU2EtTXF5c3BqV2NNTlF2VTY3aEcwTG9INi00QUJHaTlTbUNZTU1Fd0FubjFzTXk5VnpFYjF3QXZkZWw5a0xGdUZUNXZnYjdDb0hRZlphbE1sbXBENTF5S2tkQVBLUFc2M3c3R3FUY1BQWnlSUi03N1R5cmtaOEpMd0hFRUo3UmhCeG56YVdWZDR2VXdEN29ZeWw1SERRMjYtZV8xM3hvUjBCTzZCbkZ3UkJhUVp5ZDVmYnlWbnVzTUlkLWh0cmtGVHU1VlJLY1h0WWVXcUpTc0RpcDR3OTZNbm53blpfQm9Nems?oc=5","date":"2026-04-07","type":"pipeline","source":"Barchart.com","summary":"Herpes Zoster Treatment Market Size in the 7MM is projected to increase at a significantly CAGR by 2036, estimates DelveInsight - Barchart.com","headline":"Herpes Zoster Treatment Market Size in the 7MM is projected to increase at a significantly CAGR by 2036, estimates Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwJBVV95cUxNcnZpNF8tTkEwUUUtbVA1eFpHdEhHVFVWSWh0YnlUa1F5dWxCdWNZcXJJNjFabEwwZk53M1FMOTJZUFNZRXVwd1c2blZqVWZ3UmUxc1ExOWg0M2VXNXBIbHBsOVpGQkdEbzdqYTRWbzF2al9kMXZ0QjlZRDVjMTlRR2Y2M2x1MnBtVXFnSEdLWU1uOGRfdmh2dWlMZDU1QUJLOHpmLUphRFM2RFNMRHV0SlppUWxsUHI4QlZBXzlud1dpbTlUWG5XSFM2QS00S0kyNUVhMmFVZURSbGRURTJlYW1uVkc5Q3JIYmFzd1Q1XzhRb0hxODFZYldVXzVveDVlb0J3R1ZRR1czWENsRTJYZG9MYmhwN1k?oc=5","date":"2026-01-19","type":"pipeline","source":"PR Newswire UK","summary":"Underactive Bladder Syndrome Market to Observe Stunning Growth at a CAGR of 22.1% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire UK","headline":"Underactive Bladder Syndrome Market to Observe Stunning Growth at a CAGR of 22.1% During the Forecast Period (2025-2034)","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}